Psilocybin, the psychoactive compound found in certain mushrooms, is beginning to transition from a federally prohibited substance to a regulated therapeutic modality at the state level in the United States. While it remains classified as a Schedule I substance under the Controlled Substances Act, clinical research, state level legalization, and investor interest are driving the early formation of a new healthcare market.
For retail insurance agents, this represents the emergence of a specialized and complex category of healthcare professional liability (HPL) risk. Similar to the early development of ketamine clinics and transcranial magnetic stimulation (TMS) services, psilocybin treatment exists within a fragmented regulatory environment, evolving clinical standards, and limited insurance precedent.
This article explains what medical psilocybin is, how regulated programs are structured, the size and trajectory of the market, and the insurance challenges associated with placing coverage for these risks.
Psilocybin is a naturally occurring psychedelic compound that affects perception, cognition, and mood. Modern clinical research has focused on its potential to treat [1]:
The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to psilocybin assisted therapy for major depressive disorder, indicating strong preliminary evidence of clinical benefit and an accelerated review pathway[2]. Clinical trials conducted by institutions such as Johns Hopkins University have shown that supervised psilocybin sessions, combined with psychotherapy, can produce significant and sustained reductions in depressive symptoms[3].
Despite this progress, psilocybin remains federally illegal outside of approved research settings, creating a regulatory disconnect between clinical advancement and legal status.
In the absence of federal legalization, psilocybin access is currently being developed through state level frameworks.
Established through Measure 109 in 2020.
Fully implemented in 2023 under the Oregon Health Authority.
Allows licensed facilities to administer psilocybin in supervised settings.
Does not require a medical diagnosis or physician prescription.
Under this model, psilocybin is delivered as a facilitated service, not a traditional prescription drug[4].
This patchwork regulatory environment means that psilocybin services are highly jurisdiction specific, with significant variation in licensing, oversight, and operational requirements.
Because psilocybin therapy is not currently recognized or regulated at a federal level, treatment can vary dramatically by district or region. However, Oregon Psilocybin Services provides us with an example of what a regulated environment may look like. Following OPS regulations, treatment is structured as a multi-phase process rather than a single clinical encounter[7]:
Facilities providing these services are commonly referred to as psilocybin service centers or psychedelic therapy clinics. Staffing models generally include licensed or certified facilitators, with varying levels of medical oversight depending on state regulations.
Although the regulated U.S. psilocybin market is still in its early stages, broader psychedelic therapy data provides insight into its trajectory.
Grand View Research estimated the global psychedelic drugs market at approximately $3.6 billion in 2023, with a projected compound annual growth rate exceeding 15 percent through 2030[8]. North America is expected to lead early adoption due to regulatory experimentation and concentration of clinical research.
While current revenue from psilocybin services is limited to early adopter states like Oregon, expansion into additional jurisdictions is expected to drive rapid growth over the next decade.
The prevalence of depression, anxiety, and substance use disorders continues to increase, creating demand for alternative therapies[9].
Peer reviewed research and FDA designations are strengthening the credibility of psilocybin as a therapeutic tool[10][11].
State level legalization efforts are creating pathways for legal operation despite federal restrictions[12][13].
Most psilocybin services are currently paid out of pocket, with session costs often ranging from $2,000 to $5,000, reducing reliance on traditional reimbursement structures[14].
Venture capital and private equity firms are actively investing in psychedelic therapy platforms, clinic operators, and drug development companies[15][16].
Psilocybin presents a set of challenges not typically found in traditional healthcare risks:
As a result, most placements occur in the surplus lines market.
Primary exposure arises from:
Improper screening or failure to identify contraindications
Adverse psychological reactions
Inadequate supervision during sessions
Failure in post session integration
Because standards of care are still evolving, underwriters place significant emphasis on protocols and training.
Covers premises related risks, including:
Client injury during treatment sessions
Slip and fall incidents
Property damage
Extended session duration and altered states increase supervision related exposure.
Applies to:
Administrative failures
Misrepresentation of services
Regulatory noncompliance
Important for investor backed organizations. Exposure includes:
Governance failures
Regulatory violations
Misrepresentation to investors
Psilocybin providers manage sensitive behavioral health data, creating exposure to:
Data breaches
HIPAA related liabilities (where applicable)
Ransomware attacks
Underwriters evaluating psilocybin risks typically require detailed information on:
Given the novelty of the risk, underwriting scrutiny is often significantly higher than for traditional outpatient healthcare providers.
Psilocybin providers cannot be underwritten as standard behavioral health practices. Their exposure includes:
Controlled substance liability
Extended patient interaction periods
Altered patient cognition
Standard policies are often insufficient or misaligned with actual operations.
Many insureds:
Do not fully understand their risk profile
Carry policies with exclusions for key exposures
This creates both client risk and potential E&O exposure for retail agents.
As the market grows, agents who understand:
Regulatory frameworks
Clinical delivery models
Will be positioned to lead in a specialized, high growth segment of healthcare insurance.
Medical psilocybin is in the early stages of becoming a regulated healthcare service in the United States. While federal legality remains unresolved, state level programs, clinical validation, and market demand are driving rapid development.
For retail insurance agents, this presents both complexity and opportunity. The regulatory environment is fragmented, underwriting is specialized, and standard coverage solutions are often inadequate. However, agents who develop expertise in this space can position themselves at the forefront of a growing and underserved market.
Understanding the risk now is the first step toward placing it effectively as the market matures.
Psilocybin services are part of a broader shift toward new behavioral health treatment models. These risks require specialized underwriting knowledge and access to appropriate carriers.
Ethos Insurance Partners works with retail insurance agents to:
Our goal is to help you place coverage that aligns with how these businesses actually operate.
The market is active, growing, and underserved. Don’t wait. Click to Call, Email, or Schedule a Meeting now!
[1] Analysis of Psilocybin-Assisted Therapy in Medicine: A Narrative Review
https://pmc.ncbi.nlm.nih.gov/articles/PMC8901083/
[2] [10] Psychedelics: Threshold of a Therapeutic Revolution
https://pubmed.ncbi.nlm.nih.gov/37247807/
[3] [11] Psilocybin Treatment for Major Depression Effective for Up to a Year for Most Patients, Study Shows
[4] [12] Oregon Health Authority – Oregon Psilocybin Services
https://www.oregon.gov/oha/ph/preventionwellness/pages/oregon-psilocybin-services.aspx
[5] [13] Natural Medicine Division Newsroom - Colorado
https://dnm.colorado.gov/natural-medicine-frequently-asked-questions
[6] Psychedelics Legalization & Decriminalization Tracker
https://psychedelicalpha.com/resources/psychedelic-laws/
[7] The Perilous Policy of Oregon's Psilocybin Services
https://jaapl.org/content/51/2/160
[8] Psychedelic Drugs Market Size, Share & Growth Report 2030
https://www.grandviewresearch.com/industry-analysis/psychedelic-drugs-market-report
[9] Mental Health Issues Increased Significantly in Young Adults Over Last Decade
https://www.apa.org/news/press/releases/2019/03/mental-health-adults
[14] Oregon Psilocybin Therapy Clients Tend to be Wealthier, New Data Suggests
[15] PE Plays It Safe in Psychedelic Investments While Venture Goes Bold
[16] Psychedelic Commercialization: A Wide-Spanning Overview of the Emerging Psychedelic Industry
https://pmc.ncbi.nlm.nih.gov/articles/PMC11661494/
[17] Controlled Substances - Alphabetical Order - SUBSTANCE CSCN CSA SCH NARC
https://www.deadiversion.usdoj.gov/schedules/orangebook/c_cs_alpha.pdf